Dec 14 Reuters Shares of AstraZeneca fell 8 early on Monday, hit by doubts about the British firms strategy and speculation of a rival bid after it announced the 39 billion purchase of Alexion Pharmaceuticals over the weekend.
Chief Executive Officer Pascal Soriot had told reporters on Saturday that the deal, a bet on raredisease and immunology drugs, was the result of exclusive talks and no competitive bidder was involved.
The move also helps AstraZeneca, which is also working on a COVID19 vaccine, diversify from its fastgrowing cancer business.
Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur
What's your reaction?